Pharmacological inhibition of protein kinase R by C16: A multifaceted modulator of stress-induced cell death
Cell Death · 2026
DOI: 10.1016/j.celld.2026.100004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Death, 2026. Verfasst von Yoko Hirata und 4 weiteren Autor:innen. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Society for the Promotion of Science London.
Abstract (Originalsprache)
Protein kinase R (PKR) is a serine/threonine kinase activated by double-stranded RNA and various cellular stresses, and functions as a key regulator of translational control and stress-induced signaling. PKR activation contributes to multiple modes of cell death, including apoptosis and other regulated forms of stress-associated cell death, thereby linking PKR to diverse pathological conditions, such as neurodegenerative, metabolic, and cardiovascular disorders, as well as cancer and inflammation. Among the pharmacological modulators of PKR, the small-molecule inhibitor C16 (imoxin) has been widely used as a tool compound to investigate PKR-related mechanisms. C16 effectively suppresses apoptosis and endoplasmic reticulum stress–associated cell death, and attenuates ferroptosis-associated cellular and tissue damage in both cellular and animal models, demonstrating strong cytoprotective and anti-inflammatory effects. In addition to its PKR-inhibitory activity, C16 exhibits intrinsic antioxidant properties that contribute to its protective effects. This review summarizes the molecular basis of PKR signaling and the pharmacological profiles of C16 and related inhibitors, highlighting recent advances in PKR-targeted strategies for modulating stress-associated cell death. The mechanistic insights presented here may facilitate the design of next-generation PKR inhibitors with improved selectivity and enhanced therapeutic potential. • PKR integrates multiple cellular stress signals leading to translational and apoptotic control. • The small-molecule inhibitor, C16 (imoxin), suppresses PKR activation and cell death. • C16 exhibits both PKR-inhibitory and intrinsic antioxidant activities. • PKR inhibitors act either by binding to the ATP site or by disrupting the PKR–PACT interaction. • Advances in PKR-targeted inhibitor design provide new therapeutic perspectives.
Förderung
- Japan Society for the Promotion of Science
- Japan Society for the Promotion of Science London
Zitieren
APA
Hirata, Y., Yagyu, K., Kamatari, Y. O., Furuta, K., & Takemori, H. (2026). Pharmacological inhibition of protein kinase R by C16: A multifaceted modulator of stress-induced cell death. Cell Death. https://doi.org/10.1016/j.celld.2026.100004
Vancouver
Hirata Y, Yagyu K, Kamatari YO, Furuta K, Takemori H. Pharmacological inhibition of protein kinase R by C16: A multifaceted modulator of stress-induced cell death. Cell Death. 2026. doi:10.1016/j.celld.2026.100004
BibTeX
@article{Hirata2026,
author = {Hirata, Yoko and Yagyu, Kazuya and Kamatari, Yuji O. and Furuta, Kyoji and Takemori, Hiroshi},
title = {Pharmacological inhibition of protein kinase R by C16: A multifaceted modulator of stress-induced cell death},
journal = {Cell Death},
year = {2026},
doi = {10.1016/j.celld.2026.100004}
}
EUVIMED